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A series of some new 2,5-disubstituted-1,3,4-oxadiazoles 4(a–i) have been conveniently synthesized by intramolecular oxidative
cyclization of (E)-2-(arylbenzylidene)-2-[(4-methoxyphenyl)amino]acetohydrazides promoted by iodobenzene diacetate as an
oxidant. The structures of the synthesized compounds have been confirmed by 1H and 13C NMR, IR, MS, and elemental analysis.
All the newly synthesized compounds were screened for their anticonvulsant activity against maximal electroshock (MES) seizure
method. Compounds 4g, 4d, and 4awere found to be themost potent of this series.The same compounds showed no neurotoxicity
at the maximum dose administered.
1. Introduction
Epilepsy is one of the most common neurological disorders
affecting a large section of people. About 50 million people
worldwide have epilepsy, with almost 90% of these people
being in developing countries [1]. Epilepsy also affects about
4% of individuals over their lifetime. The incidence of epi-
lepsy is highest among children below 7 years of age and in
individuals of above 55 years. Epilepsy is the third most wide
spread neurological disorder found in the elderly after cere-
brovascular disease and dementia. About 20–30% of patients
have seizures that are resistant to available medical therapies
[2]. All currently approved antiepileptic drugs have dose-
related toxicity and idiosyncratic side effects [3]. Therefore,
the search for a newer, more effective, and more selective
agent with lesser side effects continues to be an area of investi-
gation of medicinal chemists worldwide.
The anticonvulsant drug design is based on the major
characteristics important in newly synthesized compounds
which are the inclusion of a hydrophobic site and H-bond
donors/acceptors in the compound which is required for
the activity in MES. Although several new drugs such
as vigabatrin, lamotrigine, gabapentin, tiagabine, felbamate,
topiramate, fosphenytoin, and levetiracetam have appeared
in the market, the development of novel agents, particu-
larly compounds effective against complex partial seizures,
remains a major focus of antiepileptic drug research.
Heterocyclic compounds containing fivemembered rings
gained importance because of their versatile biological prop-
erties. In particular, compounds bearing 1,3,4-oxadiazoles
nucleus are known have to anti-inflammatory activity [4].
Differently substituted oxadiazole molecules possess other
interesting properties such as analgesic [5], antimicrobial
[6], anti-HIV [7], antitumor [8], antihypertensive [9], anti-
tumor [10], anticonvulsant [11], 5-HT-receptor antagonists
[12], and glycogen phosphorylase inhibitors [13]. In the
present study, new 2,5-disubstituted-1,3,4-oxadiazole deriva-
tives 4(a–i) have been synthesized and characterized by dif-
ferent spectral studies. Their anticonvulsant effects are deter-
mined through maximal electroshock (MES) seizure test.
2. Experimental
All solvents and reagents were purchased from SigmaAldrich
Chemicals Pvt. Ltd. Melting range was determined by
Veego Melting Point VMP III apparatus. Elemental analyses
were recorded on VarioMICRO superuser V1.3.2 Elementar.
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The IR spectra were recorded using KBr discs on FT-IR Jasco
4100 infrared spectrophotometer. 1H and 13C NMR spectra
were recorded on Bruker DRX-500 spectrometer at 400MHz
using DMSO-d
6
as solvent and TMS as an internal standard.
The mass spectra of the samples were recorded using the
instrument LC-MSD-Trap-XCT.
2.1. Synthesis of 2-(4-Methoxyphenylamino)acetohydrazide
(2). To a mixture of ethyl-(4-methoxyphenyl)glycinate 1
(0.01mmol) and ethanol (25mL), hydrazine hydrate (0.02
mmol) was added. The reaction mass was heated to reflux
for 4 h. The reaction completion was monitored by thin layer
chromatography (TLC). The reaction mixture was concen-
trated to half volume. The solid obtained was filtered and
washed with chilled ethanol. The obtained solid was dried to
get the pure product. Yield 78%; mp 116–118∘C.
2.2. General Procedure for the Synthesis of (E)-2-(Arylbenzyl-
idene)-2-[(4-methoxyphenyl)amino]acetohydrazides (3a–i).
2-(4-Methoxyphenylamino)acetohydrazide 2 (0.001mmol)
was refluxed with different aryl aldehydes (0.001mmol) in
ethanolic solution (10mL) for about 2 h. Completion of the
reaction was confirmed by the thin layer chromatography
(TLC). After completion, reaction mass was cooled to 5 to
10∘C for 1 hr. Reaction mass was filtered and washed with
chilled ethanol. The obtained solid was dried to get the pure
product.
2.2.1. (E)-N-(4-Chlorobenzylidene)-2-[(4-methoxyphenyl)
amino]acetohydrazide 3a. The general experimental pro-
cedure described above afforded 3a and the product obtained
from 2-(4-methoxyphenylamino)acetohydrazide 2 and 4-
chlorobenzaldehyde. Yield 92%; mp 170–172∘C; 1H NMR
(DMSO-d
6





), 6.36 (s, NH), 7.03 (d, 2H, Ar-H), 7.44 (d,
2H, Ar-H), 7.68 (d, 2H, Ar-H), 8.14 (d, 2H, Ar-H), 8.60 (s,
N=CH), 9.30 (s, NH).
2.2.2. (E)-N-(4-Methylbenzylidene)-2-[(4-methoxyphenyl)
amino]acetohydrazide 3b. The general experimental pro-
cedure described above afforded 3b and the product obtained
from 2-(4-methoxyphenylamino)acetohydrazide 2 and 4-
methylbenzaldehyde. Yield 86%; mp 158–161∘C; 1H NMR
(DMSO-d
6
, 400MHz) 𝛿: 2.19 (s, 3H, Ar-CH
3
), 3.88 (s, 3H,
–OCH
3
), 4.58–4.60 (d, –CH
2
), 6.37 (s, NH), 7.55–7.76 (m,
4H, Ar-H), 8.0–8.15 (m, 4H, Ar-H), 8.55 (s, N=CH), 9.24 (s,
NH).
2.2.3. (E)-N-(4-Hydroxybenzylidene)-2-[(4-methoxyphenyl)
amino]acetohydrazide 3c. The general experimental proce-
dure described above afforded 3c and the product obtained
from 2-(4-methoxyphenylamino)acetohydrazide 2 and 4-
hydroxybenzaldehyde. Yield 90%, Mp 170–172∘C. 1H NMR
(DMSO-d
6





), 5.20 (s, 1H, OH), 6.36 (s, NH), 6.97 (dd, 2H, Ar-H),
7.22–7.38 (m, 4H, Ar-H), 7.89 (dd, 2H, Ar-H), 8.49 (s, N=CH),
9.19 (s, NH).
2.2.4. (E)-N-(3-Chlorobenzylidene)-2-[(4-methoxyphenyl)
amino]acetohydrazide 3d. The general experimental pro-
cedure described above afforded 3d and the product obtained
from 2-(4-methoxyphenylamino)acetohydrazide 2 and 2-
chlorobenzaldehyde. Yield 91%; mp 166–168∘C; 1H NMR
(DMSO-d
6





), 6.35 (s, NH), 7.04–7.12 (d, 4H, Ar-H), 7.59-(s, 1H,
Ar-H), 7.68–7.79 (m, 3H, Ar-H). 8.51 (s, N=CH), 9.32 (s, NH).
2.2.5. (E)-N-(2-Fluoro-3-methoxybenzylidene)-2-[(4-methox-
yphenyl)amino]acetohydrazide 3e. The general experimental
procedure described above afforded 3e and the product
obtained from 2-(4-methoxyphenylamino)acetohydrazide 2
and 2-fluoro-3-methoxybenzaldehyde. Yield 87%; mp 138–
140∘C; 1H NMR (DMSO-d
6
, 400MHz) 𝛿: 3.86 (s, 3H,
–OCH
3
), 3.88 (s, 3H, –OCH
3
), 4.58–4.59 (d, –CH
2
), 6.38 (s,
NH), 7.06 (dd, 2H,Ar-H), 7.31–7.34 (t, 1H, Ar-H), 7.37–7.39 (m,
4H, Ar-H), 8.48 (s, N=CH), 9.29 (s, NH).
2.2.6. (E)-N-(4-Methoxybenzylidene)-2-[(4-methoxyphenyl)
amino]acetohydrazide 3f. The general experimental proce-
dure described above afforded 3f and the product obtained
from 2-(4-methoxyphenylamino)acetohydrazide 2 and 4-
methoxybenzaldehyde. Yield 93%; mp 170–172∘C; 1H NMR
(DMSO-d
6





), 6.36 (s, NH), 6.99 (dd, 8.26Hz, 4H, Ar-H), 7.76–7.90
(m, 4H, Ar-H), 8.44 (s, N=CH), 9.33 (s, NH).
2.2.7. (E)-2-[(4-Methoxyphenyl)amino]-N-[4-(trifluorometh-
yl)benzylidene]acetohydrazide 3g. The general experimental
procedure described above afforded 3g and the product
obtained from 2-(4-methoxyphenylamino)acetohydrazide 2
and 3-trifluorobenzaldehyde. Yield 92%; mp 196–198∘C; 1H
NMR (DMSO-d
6





), 6.36 (s, NH), 7.01 (dd, 2H, Ar-H), 7.67 (dd,
2H, Ar-H), 8.04–8.13 (m, 4H, Ar-H), 8.43 (s, N=CH), 9.31 (s,
NH).
2.2.8. (E)-2-[(4-Methoxyphenyl)amino]-N-(2-nitrobenzylid-
ene)acetohydrazide 3h. The general experimental procedure
described above afforded 3h and the product obtained from
2-(4-methoxyphenylamino)acetohydrazide 2 and 2-nitrob-
enzaldehyde. Yield 90%; mp 179–181∘C; 1HNMR (DMSO-d
6
,
400MHz) 𝛿: 3.87 (s, 3H, –OCH
3
), 4.56–4.58 (d, –CH
2
),
6.36 (s, NH), 7.08 (dd, 2H, Ar-H), 7.77–7.82 (m, 5H, Ar-H),
8.10–8.15 (m, 1H, Ar-H), 8.40 (s, N=CH), 9.35 (s, NH).
2.2.9. (E)-N-(4-Bromobenzylidene)-2-[(4-methoxyphenyl)
amino]acetohydrazide 3i. The general experimental pro-
cedure described above afforded 3i and the product obtained
from 2-(4-methoxyphenylamino)acetohydrazide 2 and 4-bro
mobenzaldehyde. Yield 88%; mp 177–179∘C; 1H NMR
(DMSO-d
6





), 6.35 (s, NH), 7.05–7.15 (m, 4H, Ar-H), 7.45 (d, 2H,
Ar-H), 8.3 (d, 2H, Ar-H), 8.48 (s, N=CH), 9.29 (s, NH).
Journal of Chemistry 3
2.3. General Procedure for the Synthesis of 2,5-Disubstituted-
1,3,4-Oxadiazoles (4a–i). (E)-2-(Arylbenzylidene)-2-[(4-
methoxyphenyl)amino]acetohydrazides (3a–i) (0.01mmol)
was dissolved in methanol, and IBD (0.012mmol) was added
to it. The content was stirred for 2 h, and the progress of the
reaction was monitored by TLC. Upon completion of the
reaction, solvent was removed under reduced pressure, and
residue was taken in petroleum ether, and stirred for 30min.
The solid thus obtained was filtered, washed with petroleum
ether and dried to afford (4a–i). The crude product was
purified by recrystallization method using diethyl ether.
2.3.1. N-[{5-(4-Chlorophenyl)-1,3,4-oxadiazole-2-yl}methyl]-
4-methoxyaniline 4a. White solid. IR (KBr, cm−1): 3067
(aromatic C–H), 2924 (C–H of CH
2
), 1686 (C=N), 1462
(C=C), 1376 (C–N), 1256 (C–O). 1H NMR (DMSO-d
6
,
400MHz) 𝛿: 3.88 (s, 3H, –OCH
3
), 4.57–4.60 (d, –CH
2
), 6.32
(s, NH), 7.09 (d, 2H, Ar-H), 7.57 (d, 2H, Ar-H), 7.74 (d, 2H,
Ar-H), 8.02 (d, 2H, Ar-H). 13C NMR (DMSO-d
6
, 400MHz)
𝛿; 55.8, 115.7, 127.9, 130.2, 134.8, 158.9, 161.6, 164.1. MS (ESI)








(in %): C, 60.86; H,
4.47; N, 13.31. Found: C, 60.84; H, 4.41; N, 13.39.
2.3.2. N-[{5-(4-Methylphenyl)-1,3,4-oxadiazole-2-yl}methyl]-
4-methoxyaniline 4b. White solid. IR (KBr, cm−1): 3076 (aro-
matic C–H), 2948 (C–H of CH
2
), 1681 (C=N), 1469 (C=C),
1385 (C–N), 1239 (C–O). 1H NMR (DMSO-d
6
, 400MHz)
𝛿: 2.17 (s, 3H, Ar-CH
3





), 6.34 (s, NH), 7.55 (d, 2H, Ar-H), 7.88 (d, 2H, Ar-
H), 8.17 (d, 2H, Ar-H). 8.0–8.15 (m, 2H, Ar-H). 13C NMR
(DMSO-d
6
, 400MHz) 𝛿; 28.3, 55.8, 115.0, 116.0, 120.0, 124.6,









(in %): C, 69.14; H, 5.80; N, 14.23. Found: C,
69.10; H, 5.60; N, 14.35.
2.3.3. 4-[5-{(4-Methoxyphenyl)amino}methyl]-1,3,4-oxadia-
zole-2-yl]phenol 4c. Pale brown solid. IR (KBr, cm−1): 3516
(OH), 3071 (aromatic C–H), 2926 (C–H of CH
2
), 1646
(C=N), 1467 (C=C), 1380 (C–N), 1253 (C–O). 1H NMR
(DMSO-d
6





), 5.22 (s, 1H, OH), 6.33 (s, NH), 6.88 (dd, 2H,
Ar-H), 7.19–7.32 (m, 4H, Ar-H), 7.82 (d, 2H, Ar-H). 13CNMR
(DMSO-d
6
, 400MHz) 𝛿; 55.4, 114.7, 116.1, 125.6 130.1, 134.2,









(in %): C, 64.64; H, 5.09; N, 14.13. Found: C,
64.42; H, 4.89; N, 14.10.
2.3.4. N-[{5-(3-Chlorophenyl)-1,3,4-oxadiazole-2-yl}methyl]-
4-methoxyaniline 4d. Pale yellow solid. IR (KBr, cm−1):
3065 (aromatic C–H), 2941 (C–H of CH
2
), 1614 (C=N),
1445 (C=C), 1380 (C–N), 1241 (C–O). 1H NMR (DMSO-d
6
,
400MHz) 𝛿: 3.87 (s, 3H, –OCH
3
), 4.56–4.58 (d, –CH
2
), 6.33
(s, NH), 7.04 (d, 4H, Ar-H), 7.59–7.66 (d, 1H, Ar-H), 7.76
(d, 2H, Ar-H), 7.68–7.79 (m, 1H, Ar-H). 13C NMR (DMSO-
d
6
, 400MHz) 𝛿; 55.3, 114.2, 116.7, 120.4, 124.7, 128.2, 128.8,









(in %): C, 60.86; H, 4.47; N, 13.31. Found: C,
60.89; H, 4.64; N, 13.51.
2.3.5. N-[{5-(2-Fluoro-3-methoxyphenyl)-1,3,4-oxadiazole-2-
yl}methyl]-4-methoxyaniline 4e. White solid. FT-IR (KBr,
cm−1): 3069 (aromatic C–H), 2957 (C–H of CH
2
), 1662
(C=N), 1484 (C=C), 1381 (C–N), 1236 (C–O). 1H NMR
(DMSO-d
6
, 400MHz) 𝛿: 3.87 (s, 3H, –OCH
3
), 3.89 (s, 3H,
–OCH
3
), 4.57–4.59 (d, –CH
2
), 6.36 (s, NH), 7.06 (dd, 2H, Ar-
H), 7.10–7.14 (t, 1H, Ar-H), 7.37–7.39 (m, 2H, Ar-H), 7.84 (dd,
2H, Ar-H), 13C NMR (DMSO-d
6
, 400MHz) 𝛿; 55.8, 113.9,
116.0, 124.2, 126.1, 133.0, 136.0, 157.1, 162.8, 164.9.MS (ESI)m/z:








(in %): C, 62.00; H, 4.90;
N, 12.76. Found: C, 62.10; H, 4.84; N, 12.82.
2.3.6. 4-Methoxy-N-[{4-methoxyphenyl)-1,3,4-oxadiazole-
2-yl}methyl]aniline 4f. White solid. FT-IR (KBr, cm−1):
3047 (aromatic C–H), 2941 (C–H of CH
2
), 1629 (C=N),
1481 (C=C), 1386 (C–N), 1246 (C–O). 1H NMR (DMSO-d
6
,
400MHz) 𝛿: 3.85 (s, 6H, –OCH
3
), 4.56–4.58 (d, –CH
2
),
6.34 (s, NH), 6.94 (dd, 4H, Ar-H), 7.76 (dd, 2H, Ar-H). 13C
NMR (DMSO-d
6
, 400MHz) 𝛿; 55.3, 114.2, 116.7, 120.4, 129.8,









(in %): C, 65.58; H, 5.50; N, 13.50. Found: C,
65.51; H, 5.46; N, 13.34.
2.3.7. 4-Methoxy-N-[{5-(4-trifluoromethyl)phenyl}-1,3,4-oxa-
diazole-2-yl]methyl]aniline 4g. White solid. FT-IR (KBr,
cm−1): 3069 (aromatic C–H), 2951 (C–H of CH
2
), 1675
(C=N), 1469 (C=C), 1385 (C–N), 1231 (C–O). 1H NMR
(DMSO-d
6





), 6.35 (s, NH), 7.14 (dd, 2H, Ar-H), 7.82 (dd, 2H, Ar-
H), 7.96 (dd, 2H, Ar-H), 8.0–8.15 (m, 2H, Ar-H). 13C NMR
(DMSO-d
6
, 400MHz) 𝛿; 55.8, 115.6, 116.7, 124.2, 124.6, 127.6,











(in %): C, 58.45; H, 4.04; N, 12.03.
Found: C, 58.41; H, 4.12; N, 12.00.
2.3.8. 4-Methoxy-N-[{5-(2-nitrophenyl)-1,3,4-oxadiazole-2-yl}
methyl]aniline 4h. Yellow solid. FT-IR (KBr, cm−1): 3063
(aromatic C–H), 2934 (C–H of CH
2
), 1688 (C=N), 1469
(C=C), 1385 (C–N), 1231 (C–O). 1H NMR (DMSO-d
6
,
400MHz) 𝛿: 3.87 (s, 3H, –OCH
3
), 4.54–4.59 (d, –CH
2
), 6.33
(s, NH), 7.17 (dd, 2H, Ar-H), 7.77-7.82 (m, 2H, Ar-H), 8.10–
8.15 (m, 2H, Ar-H). 13C NMR (DMSO-d
6
, 400MHz) 𝛿; 55.7,
114.9, 116.0, 121.2, 124.2, 126.1, 133.4, 136.0, 157.4, 163.6, 165.9.









58.71; H, 4.62; N, 17.12. Found: C, 58.81; H, 4.58; N, 17.21.
2.3.9. N-[{5-(4-Bromophenyl)-1,3,4-oxadiazole-2-yl}methyl]-
4-methoxyaniline 4i. FT-IR (KBr, cm−1): 3049 (aromatic C–
H), 2921 (C–HofCH
2
), 1680 (C=N), 1467 (C=C), 1380 (C–N),
1245 (C–O). 1HNMR (DMSO-d
6
, 400MHz) 𝛿: 3.86 (s, 3H, –
OCH
3
), 4.57–4.60 (d, –CH
2
), 6.33 (s, NH), 7.05 (d, 2H, Ar-H),
7.45 (d, 2H, Ar-H), 7.82 (d, 2H, Ar-H), 7.94 (d, 𝐽 = 8.65Hz,
2H, Ar-H). 13C NMR (DMSO-d
6
, 400MHz) 𝛿; 55.4, 114.7,
116.1, 126.2, 128.4, 130.1, 134.2, 136.4, 157.4, 163.2, 165.2. MS









53.55; H, 3.92; N, 11.67. Found: C, 53.23; H, 3.81; N, 11.7.




































Scheme 1: Synthetic route for the target compounds 4(a–i).
2.4. Anticonvulsant Evaluation
Animals.MaleWistar rats procured fromNational Institute of
Nutrition, Hyderabad (190–220 g), were used in the present
study. The animals were kept in individual cages for one
week to acclimatize for the laboratory conditions. They were
allowed to free access of water and food.
All the experimental procedures were carried out in
accordance with Committee for the Purpose of Control
and Supervision of Experiments on Animals (CPCSEA)
guidelines. The study was reviewed and approved by the
Institutional Animal Ethics Committee, G. Pulla Reddy
College of Pharmacy, Hyderabad, India.
Maximal Electroshock Seizure (MES) Model. Maximal elec-
troshock seizure model was used in the present study to
evaluate the anticonvulsant activity of the compounds on
male Wistar rats. Seizures were induced in rats by delivering
electroshock of 150mA for 0.2 s bymeans of a convulsiometer
through a pair of ear clip electrodes. The test compounds
(100mg/kg) were administered by oral route in the form
of solution (the compounds were dissolved in 1% sodium
carboxymethyl cellulose), 30 minutes before the maximal
electroshock seizure test. The animals were observed closely
for 2 minutes. The percentage of inhibition of seizure relative
to control was recorded and calculated [14]. Phenytoin
(100mg/kg) was used as a standard drug.
Neurotoxicity Screening.Theminimal motor impairment was
measured in mice by the rotarod test. Acute neurological
toxicity in mice was evaluated by rotarod test [14]. The mice
were trained to stay on the accelerating rotarod that rotates
at 10 revolutions per minute. The rod diameter was 3.2 cm.
Trained animals were administered with the test compounds
at dose of 100mg/kg. Neurotoxicity was indicated by the
inability of the animal to maintain equilibrium on the rod for
at least one minute in each of the three trails. Phenytoin was
used as a standard drug.
Statistical Analysis. In the present study, datawere analyzed by
one-way analysis of variance (ANOVA) followed by dunnet
test to compare difference between the groups.
3. Results and Discussion
3.1. Chemistry. The title compounds were prepared using the
synthetic strategy described in Scheme 1. The 2-(4-methoxy-
phenylamino)acetohydrazide 2 was synthesized by the reac-
tion of ethyl-(4-methoxyphenyl)glycinate 1 with hydrazine
hydrate in ethanol as per the reported procedure [15].
The (E)-2-(arylbenzylidene)-2-[(4-methoxyphenyl)amino]
acetohydrazides (3a–i) were synthesized by the reaction
of 2-(4-methoxyphenylamino)acetohydrazide 2 which was
refluxed with different substituted aldehydes in ethanolic
solution for about 2 h. A series of new 2,5-disubstituted-
1,3,4-oxadiazoles (4a–i) have been accomplished in excellent
yields by the oxidation of (E)-2-(arylbenzylidene)-2-[(4-
methoxyphenyl)amino] acetohydrazides (3a–i) of various
aryl aldehydes with one equivalent of iodobenzene diacetate
Journal of Chemistry 5
Table 1: Chemical structure and physical data of 2,5-disubstituted-1,3,4-oxadiazoles 4(a–i).
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Table 2: Effect of the tested compounds in the maximal electro-
shock seizure test.











Control (vehicle) 8.21 —
Values are expressed as mean; 𝑛 = 6 animals in each group.
E/F = extension/flexion [decrease in ratio of extension phase (in seconds)/
flexion phase (in seconds). % Protection = (control − test)/(control) ∗ 100.
(IBD) in dichloromethane. Compounds 3a–i and 4a–i are
synthesized based on reported procedure [16].
The synthesized compounds were characterized by IR,
1H-NMR, 13C-NMR, and mass spectral and elemental anal-
yses. The IR spectra of (4a–i) were recorded using KBr
pellets in the range of 4000–400 cm−1. The absorption bands
around 3065 cm−1 are assigned to the aromatic C–H stretch.
The strong bands around 2924 cm−1 are assigned to the C–
H stretch, the appearance of a medium to strong absorp-
tion bands above 1610 cm−1 due to a stretching vibration
of the azomethine (C=N) bond formation in synthesized
compounds. The 1H NMR spectrum of 4a and 4h showed
singlet in the region of 𝛿, 3.88 and 3.87, respectively, and
doublet in the region of 𝛿, 4.57 and 4.54, respectively. All the
compounds showed singlet OCH
3
group in the region of 𝛿,
3.81–3.88. The proton spectral data of 4a–i shows resonance
peak at 𝛿 6.32–6.36 ppm (s, 1H, and NH). The carbon
spectral data agree with respect to the number of protons
and their chemical shifts with the proposed structures. 13C
NMR spectra present the correct number of carbon atoms
at the appropriate chemical shift values. The mass spectra
of 4a showed molecular ion peak at m/z 317, which is in









elemental analyses data showed good agreement between
the experimentally determined values and the theoretically
calculated values within ±0.4%. The chemical structures and
physical data of all the synthesized compounds are tabulated
in Table 1.
3.2. Anticonvulsant Activity. In the present study, the anti-
convulsant activity of the nine newly synthesized 2,5-
disubstituted-1,3,4-oxadiazoles 4(a–i) was evaluated by MES
induced seizure in rats at the dose of 100mg/kg, and the
results are summarized in Table 2. Compounds 4g, 4d, and
4ademonstrated significant protective effect onMES induced
seizure. Similarly, compounds 4e, 4i, and 4h that showed
moderate protective effect and a significant difference in pro-
tectiveness were observedwhen compared to standard group.
Table 3: Neurotoxicity screening of the compounds 4(a–i).
Compound Neurotoxicity screen
0.5 h 1 h 2 h 4 h
4a 0/4 0/4 0/4 0/4
4b 0/4 0/4 1/4 1/4
4c 0/4 0/4 1/4 1/4
4e 0/4 0/4 0/4 0/4
4f 0/4 0/4 1/4 1/4
4g 0/4 0/4 0/4 0/4
4h 0/4 0/4 0/4 0/4
4i 0/4 0/4 0/4 0/4
Phenytoin 0/4 0/4 0/4 0/4
The data in the table represent ratio between the numbers of the animals that
exhibited neurotoxicity against the number of tested animals.
Compounds 4f, 4c, and 4b have relatively lower anticonvul-
sant potencies. All the compounds were examined for their
neurotoxicity onmice using rotarodmethod given in the dose
of 100mg/kg. Except for compounds 4f, 4c, and 4b, none
of the compounds showed neurotoxicity. These compounds
showed 25% toxicity compared to standard once at 2 h of oral
administration (Table 3). The structure activity relationship
study of these compounds indicates that the introduction
of a benzene ring at position 5 of 1,3,4-oxadiazole ring;
trifluoromethyl substituent at the paraposition showed the
best anticonvulsant activity in 4g. Compounds 4d and 4a
possessing a chloro group had good anticonvulsant activity
in the MES model. Both compounds did not exhibit neu-
rotoxicity at the highest administered dose. The fluoro and
methoxy groups in 4e resulted in increased anticonvulsant
activity.The presence of bromo group in 4i and nitro group in
4h shows moderate anticonvulsant activity. Anticonvulsant
activity has increased considerably when methyl group in 4b
was replaced with tolyl variation 4c. The presence of electron
releasing methoxy group in benzene ring in 4f has more
anticonvulsant activity as compared to 4c.
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